Shamburg News · 8-K filed Nov 12, 2026, 4:27 PM EST
Verrica Pharmaceuticals Reports Third Quarter 2026 Financial Results
VRCA · Verrica Pharmaceuticals Inc.
- Earnings
- Other event
- Materiality: high
Verrica Pharmaceuticals reported total revenue of $6.9 million for the quarter ended September 30, 2026, including U.S. YCANTH net product revenue of $5.7 million, up 57.9% year-over-year. The company reported a GAAP net loss of $12.4 million, or $0.58 per share, and a non-GAAP net loss of $10.5 million, or $0.49 per share, compared with a net loss of $0.3 million in the prior-year quarter. The company also said that milestones were achieved to unlock the remaining $15.0 million under its $27.5 million credit facility with an affiliate of its Chairman.
Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001193125-26-458527.
Written from the filing by Shamburg Markets. Figures are as reported by the company.